

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2017 April 21; 23(15): 2635-2818



### EDITORIAL

- 2635 Dietary compliance in celiac disease

*Freeman HJ*

- 2640 Is there still a role for the hepatic locoregional treatment of metastatic neuroendocrine tumors in the era of systemic targeted therapies?

*Cavalcoli F, Rausa E, Conte D, Nicolini AF, Massironi S*

### REVIEW

- 2651 Hepatitis B virus infection and alcohol consumption

*Iida-Ueno A, Enomoto M, Tamori A, Kawada N*

- 2660 Endoscopic management of pancreatic fluid collections-revisited

*Nabi Z, Basha J, Reddy DN*

### ORIGINAL ARTICLE

#### Basic Study

- 2673 Overexpression of fibrinogen-like protein 2 protects against T cell-induced colitis

*Bartczak A, Zhang J, Adeyi O, Amir A, Grant D, Gorczynski R, Selzner N, Chruscinski A, Levy GA*

- 2685 Changes in human hepatic metabolism in steatosis and cirrhosis

*Schofield Z, Reed MAC, Newsome PN, Adams DH, Günther UL, Lalor PF*

- 2696 Effect of *Lactobacillus rhamnosus* HN001 and *Bifidobacterium longum* BB536 on the healthy gut microbiota composition at phyla and species level: A preliminary study

*Toscano M, De Grandi R, Stronati L, De Vecchi E, Drago L*

- 2705 Effects of Hwangryunhaedok-tang on gastrointestinal motility function in mice

*Kim H, Kim I, Lee MC, Kim HJ, Lee GS, Kim H, Kim BJ*

- 2716 Role of  $\Delta$ 133p53 isoform in NF- $\kappa$ B inhibitor PDTC-mediated growth inhibition of MKN45 gastric cancer cells

*Zhang HM, Sang XG, Wang YZ, Cui C, Zhang L, Ji WS*

#### Retrospective Cohort Study

- 2723 Optimal treatment for Siewert type II and III adenocarcinoma of the esophagogastric junction: A retrospective cohort study with long-term follow-up

*Hosoda K, Yamashita K, Moriya H, Mieno H, Watanabe M*

**Retrospective Study**

2731 Colorectal and interval cancers of the Colorectal Cancer Screening Program in the Basque Country (Spain)  
*Portillo I, Arana-Arri E, Idigoras I, Bilbao I, Martínez-Indart L, Bujanda L, Gutierrez-Ibarluzea I*

2743 Performance of 18-fluoro-2-deoxyglucose positron emission tomography for esophageal cancer screening  
*Sekiguchi M, Terauchi T, Kakugawa Y, Shimada N, Saito Y, Matsuda T*

2750 Association of obesity with *Helicobacter pylori* infection: A retrospective study  
*Xu MY, Liu L, Yuan BS, Yin J, Lu QB*

2757 Outcomes and prognostic factors of patients with stage IB and II A pancreatic cancer according to the 8<sup>th</sup> edition American Joint Committee on Cancer criteria  
*Li Y, Tang CG, Zhao Y, Cao WY, Qu GF*

**Clinical Trials Study**

2763 Patients with non-viral liver disease have a greater tumor burden and less curative treatment options when diagnosed with hepatocellular carcinoma  
*Mohsen W, Rodov M, Prakoso E, Charlton B, Bowen DG, Koorey DJ, Shackel NA, McCaughan GW, Strasser SI*

2771 Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease  
*Dong S, Zhan ZY, Cao HY, Wu C, Bian YQ, Li JY, Cheng GH, Liu P, Sun MY*

**Observational Study**

2785 Age-related impairment of esophagogastric junction relaxation and bolus flow time  
*Cock C, Besanko LK, Burgstad CM, Thompson A, Kritas S, Heddle R, Fraser RJJ, Omari TI*

2795 Endoscopic ultrasound-guided cutting of holes and deep biopsy for diagnosis of gastric infiltrative tumors and gastrointestinal submucosal tumors using a novel vertical diathermic loop  
*Liu YM, Yang XJ*

2802 Non-ALT biomarkers for markedly abnormal liver histology among Chinese persistently normal alanine aminotransferase-chronic hepatitis B patients  
*Cheng JL, Wang XL, Yang SG, Zhao H, Wu JJ, Li LJ*

**CASE REPORT**

2811 One step minilaparotomy-assisted transmesenteric portal vein recanalization combined with transjugular intrahepatic portosystemic shunt placement: A novel surgical proposal in pediatrics  
*Pelizzo G, Quaretti P, Moramarco LP, Corti R, Maestri M, Iacob G, Calcaterra V*

**ABOUT COVER**

Editorial board member of *World Journal of Gastroenterology*, Oya Yucel, PhD, Associate Professor, Pediatric Department, Baskent University, Istanbul Teaching and Medical Research Hospital, Istanbul 34662, Turkey

**AIMS AND SCOPE**

*World Journal of Gastroenterology* (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7<sup>th</sup>, 14<sup>th</sup>, 21<sup>st</sup>, and 28<sup>th</sup> each month. The *WJG* Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

**INDEXING/ABSTRACTING**

*World Journal of Gastroenterology* (*WJG*) is now indexed in Current Contents<sup>®</sup>/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch<sup>®</sup>), Journal Citation Reports<sup>®</sup>, Index Medicus, MEDLINE, PubMed, PubMed Central, Digital Object Identifier, and Directory of Open Access Journals. The 2015 edition of Journal Citation Reports<sup>®</sup> released by Thomson Reuters (ISI) cites the 2015 impact factor for *WJG* as 2.787 (5-year impact factor: 2.848), ranking *WJG* as 38 among 78 journals in gastroenterology and hepatology (quartile in category Q2).

**FLYLEAF**

**I-IX** Editorial Board

**EDITORS FOR THIS ISSUE**

**Responsible Assistant Editor:** *Xiang Li*  
**Responsible Electronic Editor:** *Fen-Fen Zhang*  
**Proofing Editor-in-Chief:** *Lian-Sheng Ma*

**Responsible Science Editor:** *Ze-Mao Gong*  
**Proofing Editorial Office Director:** *Jin-Lei Wang*

**NAME OF JOURNAL**  
*World Journal of Gastroenterology*

**ISSN**  
 ISSN 1007-9327 (print)  
 ISSN 2219-2840 (online)

**LAUNCH DATE**  
 October 1, 1995

**FREQUENCY**  
 Weekly

**EDITORS-IN-CHIEF**  
**Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon**, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

**Stephen C Strom, PhD, Professor**, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

**Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology**, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

**EDITORIAL BOARD MEMBERS**  
 All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

**EDITORIAL OFFICE**  
 Jin-Lei Wang, Director  
 Yuan Qi, Vice Director  
 Ze-Mao Gong, Vice Director  
*World Journal of Gastroenterology*  
 Baishideng Publishing Group Inc  
 7901 Stoneridge Drive, Suite 501,  
 Pleasanton, CA 94588, USA  
 Telephone: +1-925-2238242  
 Fax: +1-925-2238243  
 E-mail: [editorialoffice@wjgnet.com](mailto:editorialoffice@wjgnet.com)  
 Help Desk: <http://www.fpublishing.com/helpdesk>  
<http://www.wjgnet.com>

**PUBLISHER**  
 Baishideng Publishing Group Inc  
 7901 Stoneridge Drive, Suite 501,  
 Pleasanton, CA 94588, USA  
 Telephone: +1-925-2238242  
 Fax: +1-925-2238243  
 E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
 Help Desk: <http://www.fpublishing.com/helpdesk>

<http://www.wjgnet.com>

**PUBLICATION DATE**  
 April 21, 2017

**COPYRIGHT**  
 © 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

**SPECIAL STATEMENT**  
 All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

**INSTRUCTIONS TO AUTHORS**  
 Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

**ONLINE SUBMISSION**  
<http://www.fpublishing.com>

## Hepatitis B virus infection and alcohol consumption

Ayako Iida-Ueno, Masaru Enomoto, Akihiro Tamori, Norifumi Kawada

Ayako Iida-Ueno, Masaru Enomoto, Akihiro Tamori, Norifumi Kawada, Department of Hepatology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan

**Author contributions:** Enomoto M generated the tables; Iida-Ueno A, Enomoto M, Tamori A and Kawada N wrote the manuscript.

**Conflict-of-interest statement:** Professor Norifumi Kawada has received grants from Bristol-Myers K.K. and Chugai Pharmaceutical Co., Ltd.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to:** Dr. Masaru Enomoto, Department of Hepatology, Graduate School of Medicine, Osaka City University Medical School, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan. [enomoto-m@med.osaka-cu.ac.jp](mailto:enomoto-m@med.osaka-cu.ac.jp)  
Telephone: +81-6-66453905  
Fax: +81-6-66350915

Received: November 16, 2016

Peer-review started: November 16, 2016

First decision: December 19, 2016

Revised: January 25, 2017

Accepted: March 2, 2017

Article in press: March 2, 2017

Published online: April 21, 2017

### Abstract

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and the second most common cause of cancer deaths worldwide. The top three causes of HCC are hepatitis B virus (HBV),

hepatitis C virus (HCV), and alcoholic liver disease. Owing to recent advances in direct-acting antiviral agents, HCV can now be eradicated in almost all patients. HBV infection and alcoholic liver disease are expected, therefore, to become the leading causes of HCC in the future. However, the association between alcohol consumption and chronic hepatitis B in the progression of liver disease is less well understood than with chronic hepatitis C. The mechanisms underlying the complex interaction between HBV and alcohol are not fully understood, and enhanced viral replication, increased oxidative stress and a weakened immune response could each play an important role in the development of HCC. It remains controversial whether HBV and alcohol synergistically increase the incidence of HCC. Herein, we review the currently available literature regarding the interaction of HBV infection and alcohol consumption on disease progression.

**Key words:** Entecavir; Genetic factors; Hepatocellular carcinoma; Interferon

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The mechanisms by which alcohol enhances disease progression are less well understood in chronic hepatitis B than in chronic hepatitis C. The association of light-to-moderate alcohol consumption with clinical outcomes in patients with chronic hepatitis B virus (HBV) infection appears modest. Although the threshold amount of alcohol for increasing hepatocellular carcinoma (HCC) risk remains unknown, heavy alcohol consumption significantly accelerates the progression of liver disease to cirrhosis and, ultimately, HCC. Alcohol abuse could impair the response to interferon- $\alpha$  therapy in chronic hepatitis B patients, although not fully confirmed, and can increase the risk of HCC even in patients with low HBV DNA levels during nucleoside/nucleotide therapy.

Iida-Ueno A, Enomoto M, Tamori A, Kawada N. Hepatitis B

virus infection and alcohol consumption. *World J Gastroenterol* 2017; 23(15): 2651-2659 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v23/i15/2651.htm> DOI: <http://dx.doi.org/10.3748/wjg.v23.i15.2651>

## INTRODUCTION

Primary liver cancer, predominantly hepatocellular carcinoma (HCC), is the fifth most common cancer worldwide and the second most common cause of cancer deaths, accounting for about 745000 deaths per year<sup>[1]</sup>. Approximately 45% of cases studied could be attributed to hepatitis B virus (HBV) infection, 26% to hepatitis C virus (HCV) infection, 20% to alcoholic liver disease, and 9% to other causes, including nonalcoholic steatohepatitis, intake of aflatoxin-contaminated food, diabetes and obesity<sup>[2]</sup>. Although a highly effective vaccine containing recombinant hepatitis B surface antigen (HBsAg) has been available since the early 1980s, HBV infection still affects some 240 million people globally, with the highest rates of infection in Asia and Africa, and is a leading cause of liver-related morbidity<sup>[3]</sup>. In contrast, owing to recent advances in direct-acting antiviral agents that target specific nonstructural proteins of the virus<sup>[4,5]</sup>, HCV infection is expected to be a rare disease within the next 20 years in the United States<sup>[6]</sup>.

Alcohol abuse is another important public health problem. Worldwide, about 38% of people aged 15 years or older drink alcohol, and those who do drink consume on average 17 liters of pure alcohol annually. The highest consumption rates of alcohol are concentrated in Europe and other countries in the Northern hemisphere. The World Health Organization reported that about 3.3 million deaths, or 5.9% of all global deaths, were attributable to excess alcohol use<sup>[7]</sup>. In particular, heavy alcohol consumption commonly causes progressive liver fibrosis, which will result in cirrhosis, and finally develop into HCC.

It is, thus, clinically important to determine whether alcohol intake accelerates the progression of liver disease in patients with chronic viral hepatitis (B or C). However, the association of alcohol consumption with chronic hepatitis B in the progression of liver disease has been less extensively studied than that with chronic hepatitis C. Herein, we review the available basic and clinical literature on the impact of alcohol intake on disease progression and treatment outcome in patients with chronic hepatitis B.

## BASIC BACKGROUND

### *Mechanisms of alcohol- and HBV-induced liver damage*

In general, once chronic liver injury of any etiology (hepatitis virus infection, alcoholic and nonalcoholic fatty liver disease) has occurred, damaged hepatocytes, activated sinusoidal cells, platelets, and recruited

inflammatory cells release various profibrogenic cytokines, including transforming growth factor- $\beta$ , and reactive oxygen species, which activate hepatic stellate cells (Figure 1). This process is responsible for deposition of the majority of excess extracellular matrix (predominantly collagen types I and III).


The mechanisms of alcohol-induced liver damage are complex and multifactorial. Ethanol is oxidized to acetaldehyde, mainly by alcohol dehydrogenase (ADH) in the hepatocyte cytoplasm. This is subsequently oxidized to acetate by acetaldehyde dehydrogenase (ALDH) in mitochondria. Acetaldehyde is highly toxic, and plays an important role in protein, DNA and hybrid adduct formation, prompting release of inflammatory cytokines such as tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) by Kupffer cells, and contributing to immune responses that produce antibodies against aldehyde adducts. Acetaldehyde and aldehydes induce collagen synthesis by activation of transforming growth factor- $\beta$ -dependent and independent profibrogenic pathways in which cytochrome P450 2E1 (CYP2E1) and osteopontin are involved, activating hepatic stellate cells to promote fibrosis<sup>[8]</sup>. CYP2E1 is another enzyme involved in the initial steps of alcohol metabolism and its induction is also a key response to alcohol intake, resulting in an increased production of reactive oxidative species, mainly hydrogen peroxide and superoxide anion. Oxygen radicals interact with fat molecules in a process called lipid peroxidation. Lastly, alcohol-induced immune abnormalities lead to increased intestinal permeability to a variety of substances, including endotoxins such as lipopolysaccharide, which stimulate Kupffer cells by binding with the CD14 receptor to promote fibrosis<sup>[9]</sup>.

On the other hand, HBV is not directly cytopathic; the liver injuries seen in chronic HBV infection are considered to be associated with the activity of HBV-specific CD8+ cytotoxic T cells. Cytotoxic T cells are activated through the major histocompatibility complex, and proceed to kill infected cells by discharging interferon- $\gamma$  and TNF- $\alpha$ . HBV infection usually causes inflammatory reactions characterized by the release of cytokines and chemokines, such as interleukin (IL)-1 and IL-8, and TNF- $\alpha$ . The oxidative stress induced by inflammation triggers Kupffer cells to promote stellate cell activation *via* nuclear factor- $\kappa$ B and activator protein 1. The persistent activation of these genes promotes fibrosis, leading to cirrhosis, and finally to the development of HCC<sup>[10]</sup>.

### *Interplay between alcohol and HBV in liver disease progression*

Although the mechanisms underlying the complex interaction between alcohol and hepatitis virus infection in the progression of liver disease are not fully understood, possible explanations include effects on viral replication, increases in oxidative stress, and a weakening of the immune response<sup>[11]</sup>.

Larkin *et al*<sup>[12]</sup> reported that in HBV transgenic



**Figure 1** The mechanisms of activation of hepatic stellate cells during chronic liver injury, resulting in synthesis of excess extracellular matrix. Once chronic liver injury has occurred, damaged hepatocytes, activated sinusoidal cells, platelets, and recruited inflammatory cells release various profibrogenic cytokines, which activate hepatic stellate cells, resulting in synthesis of excess extracellular matrix, such as type I and type III collagens. ECM: Extracellular matrix; IL: Interleukin; PDGF: Platelet-derived growth factor; TGF- $\beta$ : Transforming growth factor- $\beta$ ; TNF- $\alpha$ : Tumor necrosis factor- $\alpha$ .

C.B-17 SCID mice fed a standard Lieber-DeCarli ethanol liquid diet, elevated levels of HBV RNA as replicative intermediates, and increased expression of HBs, core and X antigens were observed in the liver. With ethanol, the level of HBsAg and of viral DNA in serum increased by up to 7-fold compared with mice fed the control diet. These findings may provide a partial explanation for the effects of alcohol on viral replication and the high frequency of HBV markers observed among alcoholics. Similarly, Min *et al*<sup>[13]</sup> showed that in human HepAD38 hepatoma cells infected with HBV, 100 mmol ethanol treatment approximately doubled the transcriptional activity of HBV promoters by increasing the expression of nuclear receptors such as hepatocyte nuclear factor-4 $\alpha$  and peroxisome proliferator-activated receptor- $\alpha$ . In addition, CYP2E1-induced oxidative stress potentiates the ethanol-induced transactivation of HBV.

Consistent with clinical observations, Ha *et al*<sup>[14]</sup> showed that alanine aminotransferase (ALT) was elevated in both control C57BL/6J mice and HBx transgenic mice fed a 25% ethanol liquid diet for 12 wk, relative to water-fed controls. HBx mice showed 1.4-fold higher levels of ALT than did controls and, in histological evaluations, ethanol-fed HBx transgenic livers showed more evident hepatocyte enlargement and fatty changes compared to ethanol-fed control livers, suggesting that HBx compromising of antioxidant defenses promotes alcoholic liver injury.

Lastly, Geissler *et al*<sup>[15]</sup> demonstrated that in female BALB/c mice fed the Lieber-DeCarli diet, with 24% of the total caloric intake from ethanol, followed by DNA-based immunization with a plasmid construct containing the pre-S2/S gene, the levels of antibody to hepatitis B surface proteins (anti-HBs) were marginally reduced compared with those in control mice. Cytotoxic T lymphocytes and CD4+ T helper cells derived from ethanol-fed mouse spleens responded poorly to increasing concentrations of envelope protein and peptides *in vitro*, suggesting that chronic ethanol

consumption alters the cellular immune responses to a viral structural protein. A weakened immune response may result in not only persistent HBV infection, but also an immune-tolerant state. On the contrary, excess immune response can cause hepatitis exacerbations. The relationship between the protective versus harmful immune response in HBV infection remains to be fully defined in the context of alcohol intervention.

## LIGHT-TO-MODERATE ALCOHOL CONSUMPTION AND DISEASE PROGRESSION

Although it is well documented that HCV-positive drinkers are 2 to 3 times more likely to develop HCC than abstinent individuals<sup>[16-19]</sup>, whether HBV infection and alcohol consumption synergistically increase the incidence of HCC is still controversial. Table 1 summarizes previous reports concerning the association of light-to-moderate habitual alcohol consumption with risk of HCC in patients with chronic HBV infection. The large-scale, prospective cohort REVEAL-HBV study in Taiwan, which included more than 3500 patients (aged 30-65 years), showed, during a mean follow-up of 11 years, that elevated serum HBV DNA level ( $\geq 10000$  copies/mL) is an independent risk predictor of disease progression to cirrhosis and HCC<sup>[20,21]</sup>. A regression analysis revealed that male sex, older age, seropositivity for hepatitis B e antigen (HBeAg), and habitual alcohol consumption are also significantly associated with the development of HCC. The adjusted HR (with 95%CI) for HCC was 1.6 (1.1-2.4) for habitual alcohol consumption, defined as drinking alcohol  $\geq 4$  d per week for  $\geq 1$  year<sup>[20]</sup>. In contrast, as a predictor of progression to cirrhosis, HBV DNA level was the strongest factor (RR = 10.6; 95%CI: 5.7-19.6) in a Cox proportional hazards model adjusting for HBeAg status and serum ALT level, while habitual alcohol consumption was not associated with the risk for cirrhosis (RR = 0.8; 95%CI: 0.6-1.2)<sup>[21]</sup>. In

**Table 1** Light-to-moderate habitual alcohol consumption and risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection

Author (year)	Country	Design	n	Follow-up, years	Alcohol intake	Relative risk for HCC	Ref.
Chen (2006)	Taiwan	Prospective cohort study	3653 with HBV	11	≥ 4 d/wk for ≥ 1 year	1.6	[20]
Wang (2003)	Taiwan	Prospective cohort study	2416 men with HBV	7.8	≥ 4 d/wk for ≥ 1 year	1.28	[23]
Jee (2004)	South Korea	Prospective cohort study	4495 men with HBV	10	25 g/d	1.13	[24]

HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma.

**Table 2** Heavy alcohol consumption and risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection

Author (year)	Country	Design	n	Follow-up, years	Alcohol intake	Relative risk for HCC	Ref.
Donato (2002)	Italy	Case-control study	464 with HCC (including 92 with HBV) vs 824 controls (including 44 with HBV)	NA	≥ 60 g/d	2.13	[30]
Lin (2013)	Taiwan	Retrospective cohort study	632 cirrhotics with HBV and alcohol vs 132 cirrhotics with HBV alone	2.9-5.2	≥ 80 g/d for ≥ 5 yr	1.33	[31]
Ikeda (1998)	Japan	Prospective cohort study	610 with HBV	4.1	500 kg (cumulative)	8.37	[32]

NA: Not applicable; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma.

some other large-scale studies in Asia, results were in good agreement<sup>[22-24]</sup>. Specific examples are that Wang *et al.*<sup>[23]</sup> conducted a prospective community-based cohort study of 2416 HBsAg-positive and 9421 HBsAg-negative male residents in Taiwan for a mean follow-up of 7.8 years, and found that HBsAg-positive men with habitual alcohol consumption (≥ 4 d per week for ≥ 1 year) had an increased risk of HCC compared to HBsAg-positive men without habitual alcohol consumption, but this was not significant (RR = 1.28; 95%CI: 0.78-2.10). Another prospective cohort study in Korea that followed 4495 HBsAg-positive and 433239 HBsAg-negative men for a median observation of 10 years suggested that moderate alcohol consumption (≥ 25 g of ethanol per d) raised the RR of mortality from HCC to 1.13 in HBsAg-positive men but, again, not significantly<sup>[24]</sup>.

Some study groups developed simple nomograms based on clinical and laboratory variables for predicting the risk of HCC in patients with chronic HBV infection<sup>[25-28]</sup>. Increased age and higher HBV DNA level were strong risk predictors of HCC development, and were included in all nomograms; male sex and presence of cirrhosis were included in some. Habitual alcohol consumption was included only in the nomogram derived from the REVEAL-HBV study cohorts<sup>[25]</sup>. In that nomogram, HBeAg-seronegative participants with high HBV DNA loads (≥ 100000 copies/mL) and genotype C infections had the highest risk of HCC, with 7 points added to the overall score, whereas habitual alcohol consumption had a smaller impact, with only 2 points added.

Taken together, light-to-moderate habitual alcohol consumption appears to have, at best, a modest

association with disease progression, with approximately a 1.5-fold increased risk; this effect was not always significant, especially in smaller studies.

## HEAVY ALCOHOL CONSUMPTION AND DISEASE PROGRESSION

Table 2 summarizes previous reports concerning the association between heavy alcohol consumption and risk of HCC in patients with chronic HBV infection. Although there is currently no worldwide consensus, heavy drinking is sometimes defined as consuming more than 60 g/d of alcohol for men and 40 g/d for women<sup>[29]</sup>. In Italy, Donato *et al.*<sup>[30]</sup> conducted a case-control study to investigate the dose-effect relationship between alcohol consumption and HCC, separately, in men and women. They enrolled 464 subjects with a first diagnosis of HCC (including 92 with HBV) and 824 subjects unaffected by hepatic diseases (including 44 with HBV), and found a steady linear increase in the odds ratio of HCC with increasing alcohol intake, for values of > 60 g/d in both sexes. In addition, a synergism between alcohol drinking and chronic HBV infection was found, with the odds ratio of 2.13 in HBsAg-positive drinkers consuming > 60 g per day, compared to HBsAg-positive nondrinkers or drinkers of ≤ 60 g/d. Similarly, in a retrospective cohort study of 966 cirrhotic patients in Taiwan, with a mean follow-up period of 2.9-5.2 years, the annual incidence of HCC was significantly higher in 632 cirrhotic patients with HBV infection and heavy alcohol consumption (≥ 80 g/d for ≥ 5 years) than in 132 patients with HBV infection alone (9.9% and 4.1%, respectively, *P*

< 0.001) for a RR of 1.33<sup>[31]</sup>. Likewise, a prospective cohort study in Japan that followed 610 consecutive HBsAg-positive patients for a median observation period of 4.1 years found that cumulative alcohol consumption  $\geq 500$  kg was independently associated in a multivariate analysis with the carcinogenesis rate, with a RR (95%CI) of 8.37 (2.70-25.93,  $P = 0.0002$ )<sup>[32]</sup>. Regarding mortality, Ribes *et al.*<sup>[33]</sup> followed 2352 HBsAg-positive patients for 20 years in a prospective cohort study, and found that lifetime alcohol consumption (> 60 g/d) was associated with a 6-fold increase in the risk of death from cirrhosis and HCC.

These studies indicate that heavy alcohol intake increases the incidence of HCC in patients with chronic HBV infection, although the risk threshold remains uncertain.

## ALCOHOL CONSUMPTION AND OUTCOME OF ANTIVIRAL TREATMENT

Since high HBV DNA levels in serum are associated with a higher risk of HCC, the primary aim of chronic hepatitis B treatment is sustained suppression of viral replication. HBV cannot be completely eradicated, due to the persistence of covalently closed circular DNA in the infected cell nucleus. Current guidelines recommend antiviral therapy with pegylated interferon- $\alpha$  or nucleoside/nucleotide analogues, including entecavir and tenofovir, as first-line treatment<sup>[34-36]</sup>.

In HBeAg-positive patients, female sex, high serum ALT level, low HBV DNA level, and genotype A were associated with an increased likelihood of sustained response to interferon- $\alpha$ <sup>[37]</sup>; there are no strong pre-treatment predictors of viral response in HBeAg-negative patients. In patients with HCV, alcohol abuse appears to decrease responsiveness to interferon therapy, reducing both sensitivity and compliance<sup>[38,39]</sup>. It was reported that increased oxidative stress from alcohol consumption can impair the cellular response to interferon- $\alpha$  through interference with the JAK-STAT pathway<sup>[40,41]</sup>. Although there are no data concerning an association between alcohol consumption and treatment outcomes in patients with HBV, probably because fewer patients receive interferon for treatment of chronic hepatitis B, excess alcohol could reduce the efficacy of interferon therapy by the same mechanisms reported for patients with HCV.

In patients receiving nucleoside/nucleotide analogues, high serum ALT levels, high histological activity index scores for necroinflammation, and low HBV DNA levels are pre-treatment factors predictive of favorable biochemical, serological and virological responses<sup>[42,43]</sup>. Regarding alcohol consumption, Chung *et al.*<sup>[44]</sup> reported that hazardous drinking (defined as a score of 8 or more on the Alcohol Use Disorders Identification Test) had no significant impact on the short-term outcome of 12 mo of entecavir treatment, measured as the rate of HBeAg seroconversion

and HBV DNA negativity. Long-term treatment with lamivudine for a median duration of 32.4 mo can prevent progression to end-stage liver disease<sup>[45]</sup>. Hosaka *et al.*<sup>[46]</sup> conducted a retrospective case-control study using propensity matching, and found that patients treated with 0.5 mg entecavir were significantly less likely to develop HCC than those in the control group (HR = 0.37; 95%CI: 0.15-0.91;  $P = 0.030$ ). However, HCC can develop, even in patients with sustained HBV suppression. In addition to older age, presence of cirrhosis, HBeAg positivity, and low platelet count ( $< 1.5 \times 10^5/\text{mm}^3$ ), cumulative alcohol consumption > 200 kg was one of the significant factors associated with HCC development, with a multivariate adjusted HR (95%CI) of 2.21 (1.18-4.0).

In short, alcohol abuse could impair the response to interferon- $\alpha$  therapy in chronic hepatitis B patients as well as in chronic hepatitis C patients, and can increase the risk of HCC even in patients with low HBV DNA levels during nucleoside/nucleotide therapy.

## GENETIC FACTORS

Albeit still controversial, some reports have associated genetic variants with disease progression. Table 3 is a brief summary of reported genetic polymorphisms potentially associated with increased risk of alcoholic liver disease. In subjects with ADH2\*1/\*2 or ADH2\*1/\*1, the rate of ethanol metabolism is lower, compared with those having ADH2\*2/\*2. ALDH2 gene polymorphism can determine flushing after ethanol ingestion. Flushing was reported in subjects homozygous for ALDH2\*2/\*2 and heterozygous for ALDH2\*1/\*2, but not in those homozygous for ALDH2\*1/\*1<sup>[47]</sup>. Concerning polymorphisms of the CYP2E1 gene, subjects heterozygous for the promoter alleles C1/C2 or homozygous C2/C2 are better able to metabolize alcohol, which might increase free radical generation and lipid peroxidation, and promote fatty change in the liver<sup>[9]</sup>. Recently, the isoleucine-to-methionine substitution at position 148 (rs738409 C>G) in the patatin-like phospholipase domain-containing 3 protein (PNPLA3) has been reported to have a strong association with progression of alcoholic liver disease (including cirrhosis and HCC), as well as nonalcoholic fatty liver disease<sup>[48,49]</sup>. Polymorphisms in CD14<sup>[50]</sup> or TNF- $\alpha$ <sup>[51]</sup> are reported to be associated with alcoholic liver injury, but further validation is needed.

Regarding HBV, a number of cohort studies have shown that some single nucleotide polymorphisms (SNPs) in the HLA-DP loci are associated with persistent HBV infection. As shown in Table 4, for example, rs3077 SNP near the HLA-DPA1 gene and rs9277535 SNP near the HLA-DPB1 gene were associated with persistent HBV infection in Asian populations<sup>[52]</sup>. Among Chinese, Li *et al.*<sup>[53]</sup> identified locus at 8p21.3 (index SNP rs7000921) contributing to the susceptibility to persistent HBV infection. They further demonstrated the nearby gene integrator complex subunit 10 at 8p21.3

**Table 3 Genetic polymorphisms associated with increased risk of alcoholic liver disease progression**

Gene	Polymorphism	Reported association	Ref.
<i>ADH</i>	ADH2*1/*2 ADH2*1/*1	Decrease the rate of ethanol metabolism	[47]
<i>ALDH</i>	ALDH2*2/*2 ALDH2*1/*2	Increase alcohol sensitivity	[47]
<i>CYP2E1</i>	C1/C2 C2/C2	Increase free radical generation, lipid peroxidation, and fatty change	[9]
<i>PNPLA3</i>	rs738409C>G	Increase the risk of liver cirrhosis and HCC	[48,49]
<i>CD14</i>	159TT	Enhance inflammatory responses	[50]
<i>TNF-α</i>	238G>A	Develop alcoholic liver disease	[51]

ADH: Alcohol dehydrogenase; ALDH: Acetaldehyde dehydrogenase; CYP2E1: Cytochrome P450 2E1; HCC: Hepatocellular carcinoma; PNPLA3: Patatin-like phospholipase domain containing 3; TNF-α: Tumor necrosis factor-α.

**Table 4 Genetic polymorphisms associated with hepatitis B virus infection**

Gene	Polymorphism	Reported association	Ref.
<i>HLA-DPA1</i>	rs3077 CC	Persistent HBV infection	[52]
<i>HLA-DPB1</i>	rs9277535 GG	Persistent HBV infection	[52]
<i>INTS10</i>	rs7000921 TT or CC	Suppress HBV replication Associated with clearance of HBV infection	[53]

HBV: Hepatitis B virus; HLA: Human leukocyte antigen; INTS10: Integrator complex subunit 10.

suppresses HBV replication in an interferon regulatory factor 3-dependent manner *in vitro* and identified an antiviral gene integrator complex subunit 10 (*INTS10*) at 8p21.3 as involved in the clearance of HBV infection. A SNP near the *IL-28B* gene is associated with pegylated interferon-α and ribavirin treatment-induced/spontaneous viral clearance in chronic/acute HCV infection. In contrast, in chronic hepatitis B, previous studies yielded conflicting results of the association of *IL-28B* with response to interferon-α treatment or long-term outcome<sup>[54]</sup>.

## OTHER POSSIBLE FACTORS AFFECTING DISEASE PROGRESSION

Other factors may affect the progression of alcoholic liver injury, including the disease duration, patient sex, ethnicity and obesity<sup>[9,55,56]</sup>. Since longer duration of persistent alcohol intake is associated with disease progression in patients with alcoholic liver injury, it is generally accepted that strict abstinence must be recommended. Although a retrospective case-control study unexpectedly indicated that former drinkers who had stopped 1-10 years previously had a higher risk of HCC than current drinkers, the authors speculated the reason might be that many patients with HCC had stopped drinking some years prior to the study<sup>[30]</sup>. With

regard to sex differences, women are more susceptible than men to the toxic effects of alcohol, as they have a significantly higher risk of developing progressive disease for any given level of alcohol intake<sup>[57]</sup>. In contrast, male patients with HBV are at higher risk of HCC than are female patients<sup>[58]</sup>. Previous studies on racial and ethnic differences have found that Hispanic, Black, and Asian subjects are more susceptible to alcohol-related liver damage than are Caucasians<sup>[59,60]</sup>. Additionally, in most Asian countries, genotype C is the most prevalent type of HBV, which is associated with an increased risk of disease progression<sup>[61]</sup>. As most large-scale clinical studies of HBV have been conducted in East Asia, it remains to be elucidated whether the obtained results can be applied to other areas, such as the United States and Europe. Lastly, Loomba *et al*<sup>[62]</sup> reported that alcohol and obesity synergistically increased the risk of HCC in 2260 HBsAg-positive men from the REVEAL-HBV study cohort (HR = 3.40; 95%CI: 1.24-9.34).

## CONCLUSION

The association of light-to-moderate alcohol consumption with clinical outcomes in patients with chronic HBV infection appears modest, with a 1.5-fold increased risk at best, probably smaller than that of viral factors such as HBV DNA load and genotype. However, heavy alcohol consumption significantly accelerates the progression of liver disease to cirrhosis and, finally, HCC, with a 1.3-fold to 8.4-fold increased risk. As the mechanisms by which alcohol enhances disease progression are less well understood in patients with chronic hepatitis B than C, more experimental studies are warranted. In addition, alcohol abuse could impair the response to interferon-α therapy in patients with chronic hepatitis B (as with C), although this is still controversial, and can increase the risk of HCC in patients with low HBV DNA levels suppressed by nucleoside/nucleotide therapy. Although the threshold amount of alcohol for HCC risk remains unknown, heavy alcohol intake is clearly associated with the progression of liver disease. Strict abstinence should

be recommended in patients with chronic hepatitis B.

## REFERENCES

- 1 **Ferlay J**, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015; **136**: E359-E386 [PMID: 25220842 DOI: 10.1002/ijc.29210]
- 2 **Lozano R**, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA 3rd, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De León FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; **380**: 2095-2128 [PMID: 23245604]
- 3 **World Health Organization**. Hepatitis B [Fact sheet]. Updated July 2015. Accessed October 11, 2016. Available from: URL: <http://www.who.int/mediacentre/factsheets/fs204/en/>
- 4 **Asselah T**, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. *Liver Int* 2016; **36** Suppl 1: 47-57 [PMID: 26725897 DOI: 10.1111/liv.13027]
- 5 **Tamori A**, Enomoto M, Kawada N. Recent Advances in Antiviral Therapy for Chronic Hepatitis C. *Mediators Inflamm* 2016; **2016**: 6841628 [PMID: 27022210 DOI: 10.1155/2016/6841628]
- 6 **Kabiri M**, Jazwinski AB, Roberts MS, Schaefer AJ, Chhatwal J. The changing burden of hepatitis C virus infection in the United States: model-based predictions. *Ann Intern Med* 2014; **161**: 170-180 [PMID: 25089861 DOI: 10.7326/M14-0095]
- 7 **World Health Organization**. Global status report on alcohol and health. Geneva: World Health Organization; 2014. Accessed October 11, 2016. Available from: URL: [http://www.who.int/substance\\_abuse/publications/global\\_alcohol\\_report/en/](http://www.who.int/substance_abuse/publications/global_alcohol_report/en/)
- 8 **Torok NJ**. Update on Alcoholic Hepatitis. *Biomolecules* 2015; **5**: 2978-2986 [PMID: 26540078 DOI: 10.3390/biom5042978]
- 9 **Gramenzi A**, Caputo F, Biselli M, Kuria F, Loggi E, Andreone P, Bernardi M. Review article: alcoholic liver disease--pathophysiological aspects and risk factors. *Aliment Pharmacol Ther* 2006; **24**: 1151-1161 [PMID: 17014574]
- 10 **Suhail M**, Abdel-Hafiz H, Ali A, Fatima K, Damanhoury GA, Azhar E, Chaudhary AG, Qadri I. Potential mechanisms of hepatitis B virus induced liver injury. *World J Gastroenterol* 2014; **20**: 12462-12472 [PMID: 25253946 DOI: 10.3748/wjg.v20.i35.12462]
- 11 **Gitto S**, Vitale G, Villa E, Andreone P. Update on Alcohol and Viral Hepatitis. *J Clin Transl Hepatol* 2014; **2**: 228-233 [PMID: 26356547 DOI: 10.14218/JCTH.2014.00030.Review]
- 12 **Larkin J**, Clayton MM, Liu J, Feitelson MA. Chronic ethanol consumption stimulates hepatitis B virus gene expression and replication in transgenic mice. *Hepatology* 2001; **34**: 792-797 [PMID: 11584377]
- 13 **Min BY**, Kim NY, Jang ES, Shin CM, Lee SH, Park YS, Hwang JH, Jeong SH, Kim N, Lee DH, Kim JW. Ethanol potentiates hepatitis B virus replication through oxidative stress-dependent and -independent transcriptional activation. *Biochem Biophys Res Commun* 2013; **431**: 92-97 [PMID: 23274499 DOI: 10.1016/j.bbrc.2012.12.081]
- 14 **Ha HL**, Shin HJ, Feitelson MA, Yu DY. Oxidative stress and antioxidants in hepatic pathogenesis. *World J Gastroenterol* 2010; **16**: 6035-6043 [PMID: 21182217 DOI: 10.3748/wjg.v16.i48.6035]
- 15 **Geissler M**, Gesien A, Wands JR. Chronic ethanol effects on cellular immune responses to hepatitis B virus envelope protein: an immunologic mechanism for induction of persistent viral infection in alcoholics. *Hepatology* 1997; **26**: 764-770 [PMID: 9303510]
- 16 **Novo-Veleiro I**, Alvela-Suárez L, Chamorro AJ, González-Sarmiento R, Laso FJ, Marcos M. Alcoholic liver disease and hepatitis C virus infection. *World J Gastroenterol* 2016; **22**: 1411-1420 [PMID: 26819510 DOI: 10.3748/wjg.v22.i4.1411]
- 17 **Punzalan CS**, Bukong TN, Szabo G. Alcoholic hepatitis and HCV interactions in the modulation of liver disease. *J Viral Hepat* 2015; **22**: 769-776 [PMID: 25754333 DOI: 10.1111/jvh.12399]
- 18 **Siu L**, Foon J, Wands JR. Hepatitis C virus and alcohol. *Semin Liver Dis* 2009; **29**: 188-199 [PMID: 19387918 DOI: 10.1055/s-0029-1214374]
- 19 **Fukushima W**, Tanaka T, Ohfuji S, Habu D, Tamori A, Kawada N, Sakaguchi H, Takeda T, Nishiguchi S, Seki S, Shiomi S, Hirota Y. Does alcohol increase the risk of hepatocellular carcinoma among patients with hepatitis C virus infection? *Hepatol Res* 2006; **34**: 141-149 [PMID: 16427353]
- 20 **Chen CJ**, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. *JAMA* 2006; **295**: 65-73 [PMID: 16391218]
- 21 **Iloeje UH**, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. *Gastroenterology* 2006; **130**: 678-686 [PMID: 16530509]
- 22 **Tseng TC**, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. *Gastroenterology* 2012; **142**: 1140-1149.e3; quiz e13-14 [PMID: 22333950 DOI: 10.1053/j.gastro.2012.02.007]
- 23 **Wang LY**, You SL, Lu SN, Ho HC, Wu MH, Sun CA, Yang HI, Chien-Jen C. Risk of hepatocellular carcinoma and habits of alcohol drinking, betel quid chewing and cigarette smoking: a cohort of 2416 HBsAg-seropositive and 9421 HBsAg-seronegative male residents in Taiwan. *Cancer Causes Control* 2003; **14**: 241-250 [PMID: 12814203]
- 24 **Jeon SH**, Ohrr H, Sull JW, Samet JM. Cigarette smoking, alcohol drinking, hepatitis B, and risk for hepatocellular carcinoma in Korea. *J Natl Cancer Inst* 2004; **96**: 1851-1856 [PMID: 15601641]
- 25 **Chen CJ**, Yang HI. Natural history of chronic hepatitis B REVEAled. *J Gastroenterol Hepatol* 2011; **26**: 628-638 [PMID: 21323729 DOI: 10.1111/j.1440-1746.2011.06695.x]
- 26 **Yang HI**, Yuen MF, Chan HL, Han KH, Chen PJ, Kim DY, Ahn SH, Chen CJ, Wong VW, Seto WK. Risk estimation for

- hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. *Lancet Oncol* 2011; **12**: 568-574 [PMID: 21497551 DOI: 10.1016/S1470-2045(11)70077-8]
- 27 **Yuen MF**, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, But DY, Chan AO, Wong BC, Mizokami M, Lai CL. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. *J Hepatol* 2009; **50**: 80-88 [PMID: 18977053 DOI: 10.1016/j.jhep.2008.07.023]
- 28 **Wong VW**, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, Lui YY, Chan AT, Sung JJ, Yeo W, Chan HL, Mok TS. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. *J Clin Oncol* 2010; **28**: 1660-1665 [PMID: 20194845 DOI: 10.1200/JCO.2009.26.2675]
- 29 European Medicines Agency (EMA) (2010): Guideline on the development of medicinal products for the treatment of alcohol dependence. EMA/CHMP/EWP/20097/2008. Available at: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Scientific\\_guideline/2010/03/WC500074898.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/03/WC500074898.pdf). Accessed October 11, 2016.
- 30 **Donato F**, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, Decarli A, Trevisi P, Ribero ML, Martelli C, Porru S, Nardi G. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. *Am J Epidemiol* 2002; **155**: 323-331 [PMID: 11836196]
- 31 **Lin CW**, Lin CC, Mo LR, Chang CY, Perng DS, Hsu CC, Lo GH, Chen YS, Yen YC, Hu JT, Yu ML, Lee PH, Lin JT, Yang SS. Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis. *J Hepatol* 2013; **58**: 730-735 [PMID: 23220252 DOI: 10.1016/j.jhep.2012.11.045]
- 32 **Ikeda K**, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, Arase Y, Fukuda M, Chayama K, Murashima N, Kumada H. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. *J Hepatol* 1998; **28**: 930-938 [PMID: 9672166]
- 33 **Ribes J**, Cléries R, Rubió A, Hernández JM, Mazzara R, Madoz P, Casanovas T, Casanova A, Gallen M, Rodríguez C, Moreno V, Bosch FX. Cofactors associated with liver disease mortality in an HBsAg-positive Mediterranean cohort: 20 years of follow-up. *Int J Cancer* 2006; **119**: 687-694 [PMID: 16496403]
- 34 **Terrault NA**, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. *Hepatology* 2016; **63**: 261-283 [PMID: 26566064 DOI: 10.1002/hep.28156]
- 35 **European Association For The Study Of The Liver**. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. *J Hepatol* 2012; **57**: 167-185 [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010]
- 36 **Sarin SK**, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. *Hepatology* 2016; **10**: 1-98 [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4]
- 37 **Buster EH**, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, Janssen HL. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. *Gastroenterology* 2009; **137**: 2002-2009 [PMID: 19737568 DOI: 10.1053/j.gastro.2009.08.061]
- 38 **Mochida S**, Ohnishi K, Matsuo S, Kakihara K, Fujiwara K. Effect of alcohol intake on the efficacy of interferon therapy in patients with chronic hepatitis C as evaluated by multivariate logistic regression analysis. *Alcohol Clin Exp Res* 1996; **20**: 371A-377A [PMID: 8986241]
- 39 **Ohnishi K**, Matsuo S, Matsutani K, Itahashi M, Kakihara K, Suzuki K, Ito S, Fujiwara K. Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. *Am J Gastroenterol* 1996; **91**: 1374-1379 [PMID: 8677998]
- 40 **Nguyen VA**, Gao B. Expression of interferon alfa signaling components in human alcoholic liver disease. *Hepatology* 2002; **35**: 425-432 [PMID: 11826419]
- 41 **Di Bona D**, Cippitelli M, Fionda C, Cammà C, Licata A, Santoni A, Craxi A. Oxidative stress inhibits IFN- $\alpha$ -induced antiviral gene expression by blocking the JAK-STAT pathway. *J Hepatol* 2006; **45**: 271-279 [PMID: 16595158]
- 42 **Perrillo RP**, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, Heathcote EJ, Brown NA, Atkins M, Woessner M, Gardner SD. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. *Hepatology* 2002; **36**: 186-194 [PMID: 12085364]
- 43 **Marcellin P**, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. *N Engl J Med* 2008; **359**: 2442-2455 [PMID: 19052126 DOI: 10.1056/NEJMoa0802878]
- 44 **Chung WG**, Kim HJ, Choe YG, Seok HS, Chon CW, Cho YK, Kim BI, Koh YY. Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-naïve patients with chronic hepatitis B infection. *Clin Mol Hepatol* 2012; **18**: 195-202 [PMID: 22893870 DOI: 10.3350/cmh.2012.18.2.195]
- 45 **Liaw YF**, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. *N Engl J Med* 2004; **351**: 1521-1531 [PMID: 15470215]
- 46 **Hosaka T**, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. *Hepatology* 2013; **58**: 98-107 [PMID: 23213040 DOI: 10.1002/hep.26180]
- 47 **Tanaka F**, Shiratori Y, Yokosuka O, Imazeki F, Tsukada Y, Omata M. Polymorphism of alcohol-metabolizing genes affects drinking behavior and alcoholic liver disease in Japanese men. *Alcohol Clin Exp Res* 1997; **21**: 596-601 [PMID: 9194910]
- 48 **Tian C**, Stokowski RP, Kershenovich D, Ballinger DG, Hinds DA. Variant in PNPLA3 is associated with alcoholic liver disease. *Nat Genet* 2010; **42**: 21-23 [PMID: 19946271 DOI: 10.1038/ng.488]
- 49 **Salameh H**, Raff E, Erwin A, Seth D, Nischalke HD, Falletti E, Burza MA, Leathert J, Romeo S, Molinaro A, Corradini SG, Toniutto P, Spengler U, Daly A, Day CP, Kuo YF, Singal AK. PNPLA3 Gene Polymorphism Is Associated With Predisposition to and Severity of Alcoholic Liver Disease. *Am J Gastroenterol* 2015; **110**: 846-856 [PMID: 25964223 DOI: 10.1038/ajg.2015.137]
- 50 **Campos J**, Gonzalez-Quintela A, Quinteiro C, Gude F, Perez LF, Torre JA, Vidal C. The -159C/T polymorphism in the promoter region of the CD14 gene is associated with advanced liver disease and higher serum levels of acute-phase proteins in heavy drinkers. *Alcohol Clin Exp Res* 2005; **29**: 1206-1213 [PMID: 16046876]
- 51 **Marcos M**, Gómez-Munuera M, Pastor I, González-Sarmiento R, Laso FJ. Tumor necrosis factor polymorphisms and alcoholic liver disease: a HuGE review and meta-analysis. *Am J Epidemiol* 2009; **170**: 948-956 [PMID: 19755636 DOI: 10.1093/aje/kwp236]
- 52 **Tamori A**, Kawada N. HLA class II associated with outcomes of hepatitis B and C infections. *World J Gastroenterol* 2013; **19**: 5395-5401 [PMID: 24023482 DOI: 10.3748/wjg.v19.i33.5395]
- 53 **Li Y**, Si L, Zhai Y, Hu Y, Hu Z, Bei JX, Xie B, Ren Q, Cao P, Yang F, Song Q, Bao Z, Zhang H, Han Y, Wang Z, Chen X, Xia X, Yan H, Wang R, Zhang Y, Gao C, Meng J, Tu X, Liang X, Cui Y, Liu Y, Wu X, Li Z, Wang H, Li Z, Hu B, He M, Gao Z, Xu X, Ji H, Yu C, Sun Y, Xing B, Yang X, Zhang H, Tan A, Wu C, Jia W, Li S, Zeng YX, Shen H, He F, Mo Z, Zhang H, Zhou G. Genome-wide association study identifies 8p21.3 associated with persistent hepatitis B virus infection among Chinese. *Nat Commun* 2016; **7**: 11664 [PMID: 27244555 DOI: 10.1038/ncomms11664]

- 54 **Stättermayer AF**, Ferenci P. Effect of IL28B genotype on hepatitis B and C virus infection. *Curr Opin Virol* 2015; **14**: 50-55 [PMID: 26284971 DOI: 10.1016/j.coviro.2015.07.011]
- 55 **European Association for the Study of Liver**. EASL clinical practical guidelines: management of alcoholic liver disease. *J Hepatol* 2012; **57**: 399-420 [PMID: 22633836 DOI: 10.1016/j.jhep.2012.04.004]
- 56 **O'Shea RS**, Dasarathy S, McCullough AJ. Alcoholic liver disease. *Hepatology* 2010; **51**: 307-328 [PMID: 20034030 DOI: 10.1002/hep.23258]
- 57 **Sato N**, Lindros KO, Baraona E, Ikejima K, Mezey E, Järveläinen HA, Ramchandani VA. Sex difference in alcohol-related organ injury. *Alcohol Clin Exp Res* 2001; **25**: 40S-45S [PMID: 11391047]
- 58 **Fattovich G**. Natural history and prognosis of hepatitis B. *Semin Liver Dis* 2003; **23**: 47-58 [PMID: 12616450]
- 59 **Stewart SH**. Racial and ethnic differences in alcohol-associated aspartate aminotransferase and gamma-glutamyltransferase elevation. *Arch Intern Med* 2002; **162**: 2236-2239 [PMID: 12390068]
- 60 **Wickramasinghe SN**, Corridan B, Izaguirre J, Hasan R, Marjot DH. Ethnic differences in the biological consequences of alcohol abuse: a comparison between south Asian and European males. *Alcohol Alcohol* 1995; **30**: 675-680 [PMID: 8554653]
- 61 **Enomoto M**, Tamori A, Nishiguchi S. Hepatitis B virus genotypes and response to antiviral therapy. *Clin Lab* 2006; **52**: 43-47 [PMID: 16506363]
- 62 **Loomba R**, Yang HI, Su J, Brenner D, Illoeje U, Chen CJ. Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men. *Clin Gastroenterol Hepatol* 2010; **8**: 891-898, 898.e1-2 [PMID: 20621202 DOI: 10.1016/j.cgh.2010.06.027]

**P- Reviewer:** Eyre NS, Kasprzak A, Wongkajornsilp A  
**S- Editor:** Yu J **L- Editor:** Filipodia **E- Editor:** Zhang FF





Published by **Baishideng Publishing Group Inc**  
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: [bpgooffice@wjgnet.com](mailto:bpgooffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>



ISSN 1007-9327

